We can’t show the full text here under this license. Use the link below to read it at the source.
Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid‑Coated Superparamagnetic Iron Oxide
Detecting PD-L1 Protein in Temozolomide-Resistant Brain Tumors Using Lipid-Coated Magnetic Nanoparticles
AI simplified
Abstract
PDL1-SPIO nanoparticles can specifically target with expression as confirmed through MRI analysis.
- Lipid-coated SPIO nanoparticles reduce nonspecific binding and prevent agglomeration, making them effective for molecular MRI diagnosis.
- PD-L1 is identified as a poor prognostic factor in glioblastoma patients, particularly in recurrent cases resistant to temozolomide.
- The conjugation of PD-L1 antibodies to SPIO nanoparticles enables the detection of PD-L1 expression in glioblastoma cells.
- Specific binding of PDL1-SPIO to the PD-L1 of the mouse glioblastoma cell line (GL261) was observed.
- The presence of PDL1-SPIO in tumor tissue was confirmed through Prussian blue staining and in vivo MRI analysis.
AI simplified
Key numbers
0.09 μg of antibody/μg of SPIO
Antibody Density
Concentration of antibody linked to SPIO nanoparticles.
92.4 ms at 0.98 μg/mL, decreased to 22.9 ms at 15.7 μg/mL
T2 Relaxation Time Reduction
T2 relaxation times of PDL1-SPIO at different iron concentrations.
4 h post-injection
In Vivo MRI Detection Time
Time point for maximum imaging clarity in tumor-bearing mice.